Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A craniopharyngioma consisting of broad strands, cords and bridges of a multistratified squamous epithelium with peripheral palisading of nuclei. Diagnostic features include nodules of compact 'wet' keratin and dystrophic calcification. (Adapted from WHO)
Biomarker and diagnostic research for adamantinous craniopharyngioma has been reported in the published literature.
4 clinical trials registered, 3 recruiting. Interventions under study include drug therapy. Pipeline includes 2 PHASE2, 1 PHASE1, 1 EARLY_PHASE1. Research is sponsored by a mix of industry and academic institutions.
164 publications have been identified in PubMed for adamantinous craniopharyngioma. Research spans Review / Meta-Analysis (35%), Case Report / Case Series (17%), and Basic Science / Preclinical (16%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 58 |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 3:09 PM UTC
Common questions about adamantinous craniopharyngioma
Patient case studies | 28 | 17% |
Laboratory research | 26 | 16% |
Disease patterns and progression | 19 | 12% |
Clinical study results | 13 | 8% |
Testing and diagnosis research | 10 | 6% |
Other research | 7 | 4% |
New treatment approaches | 3 | 2% |
Javid S (2026). [PMID: 41641185](https://pubmed.ncbi.nlm.nih.gov/41641185/). *Cureus*. [Case Report / Case Series]
Filce C (2026). [PMID: 41274762](https://pubmed.ncbi.nlm.nih.gov/41274762/). *Neuroimaging Clin N Am*. [Review / Meta-Analysis]
Pena-Burgos EM (2026). [PMID: 40879146](https://pubmed.ncbi.nlm.nih.gov/40879146/). *Int J Gynaecol Obstet*. [Case Report / Case Series]
Yamaki VN (2026). [PMID: 41718796](https://pubmed.ncbi.nlm.nih.gov/41718796/). *Childs Nerv Syst*. [Epidemiology / Natural History]
Chen D (2026). [PMID: 41489092](https://pubmed.ncbi.nlm.nih.gov/41489092/). *Adv Sci (Weinh)*. [Basic Science / Preclinical]
Lotfian G (2026). [PMID: 40773058](https://pubmed.ncbi.nlm.nih.gov/40773058/). *Neuroradiology*. [Case Report / Case Series]
Neubecker JJ (2026). [PMID: 41898146](https://pubmed.ncbi.nlm.nih.gov/41898146/). *Biomedicines*. [Review / Meta-Analysis]
Müller HL (2026). [PMID: 41224353](https://pubmed.ncbi.nlm.nih.gov/41224353/). *Endocr J*. [Review / Meta-Analysis]
Wang W (2026). [PMID: 42164118](https://pubmed.ncbi.nlm.nih.gov/42164118/). *Front Oncol*. [Diagnostic / Biomarker]
Zhang H (2026). [PMID: 41250940](https://pubmed.ncbi.nlm.nih.gov/41250940/). *Adv Sci (Weinh)*. [Basic Science / Preclinical]
AI-curated news mentioning adamantinous craniopharyngioma
Updated May 11, 2026
The OUTSPREAD study investigates the effects of growth hormone treatment on linear growth and metabolic outcomes in patients with childhood-onset craniopharyngioma. Findings contribute to understanding treatment impacts in this rare disease population.